Physiogenex's proprietary diet-induced (DIN) NASH mouse model. Evaluation of NASH drug efficacy in an obese and insulin-resistant environment.
The Physiogenex independently developed diet-induced NASH mouse model involves feeding a high-fat, high-cholesterol diet, along with the addition of fructose to drinking water. This induces severe liver damage, obesity, and insulin resistance. As a result, liver fat and hepatocyte ballooning appear by the 16th week of feeding, and severe liver complications (inflammation and fibrosis) develop by 25 weeks of age. Additionally, the administration of the FXR agonist obeticholic acid, which is related to NASH, results in observed reductions in obesity, insulin resistance, fatty liver, and ballooning at both 16 and 25 weeks of age. This experimental system allows for the efficacy evaluation of drugs using obeticholic acid as a control, set against a background of obesity and insulin resistance that resembles the histopathological features of human NASH. Furthermore, there are efficacy evaluation data and academic papers (PDF) using Elafibranor (GFT505) as a control drug. For more details, please contact us. *Inquiries can also be made through our website. We will respond promptly. (Search for "Clea Japan" at http://www.clea-japan.com/)
Inquire About This Product
basic information
Example: 5 groups (n=10) configuration Group 1 is the control, groups 2-4 receive the test compounds (three dosage levels), and group 5 receives a commercial drug. Protocol summary: (For details, please inquire) - Acclimatization period of 5 days for 8-week-old male mice - From 9 weeks of age, feeding a high-fat, high-cholesterol diet and providing fructose-supplemented water - 6-7 weeks after feeding and watering (at 15-16 weeks of age), randomization into groups based on plasma ALT/AST, HOMA-IR, and body weight. Start of drug administration - Parameters that can be measured: Plasma ALT/AST, HOMA-IR, liver lipids, gene expression, pathological analysis (H&E, ORO, Sirius Red staining), NAS scoring *Inquiries can also be made from our website. We will respond promptly. (Search for "Clea Japan" http://www.clea-japan.com/)
Price range
Delivery Time
※Approximately 6 months from the exam period to the final report.
Applications/Examples of results
Main Academic Presentations Presentation APASL 2016 (Poster presentation) (2016) Title P2Y13 receptor agonist CER-209, an antiatherosclerotic compound, decreases liver steatosis in vivo Presentation The Liver Meeting 2016 (November 2016) Title Farnesoid X Receptor agonist Obeticholic Acid Improves both Liver Complications and Atherosclerosis in the Obese, Insulin Resistant, Diet-Induced NASH (DIN) Mouse. A Nutritional Model for Evaluating Drugs Affecting Non-Alcoholic Liver Diseases.
Company information
Nihon Kurea Co., Ltd. is a company primarily engaged in the production and sale of laboratory animals, the manufacture and sale of laboratory animal feed, and the manufacture and sale of laboratory animal housing equipment, tools, facilities, and devices. In response to research using laboratory animals, we have been working on the development and improvement of various types of laboratory animal feed. Currently, there are 15 different brands available. These feeds are supplied under strict management from the procurement of raw materials to formulation, manufacturing, product inspection, storage, and transportation, in accordance with the regulations of the "Nihon Kurea Co., Ltd. Business Standards for Management Criteria Related to Laboratory Animal Feed," with the aim of maintaining consistently stable quality and improving reliability.
